antihemophilic factor

(redirected from Kogenate)
Also found in: Dictionary, Thesaurus, Medical.
Related to Kogenate: Xyntha

antihemophilic factor

[¦an·tē‚hē·mə′fil·ik ‚fak·tər]
(biochemistry)
A soluble protein clotting factor in mammalian blood. Also known as factor VIII; thromboplastinogen.
References in periodicals archive ?
Additionally, the safety objectives were met and adverse events were consistent with the existing safety profile for Kogenate FS.
A letter from Terry Tenbrusel, the vice president of sales and marketing for Bayer's biological products area, stated that because hospitals and hemophilia treatment centers will now have access to Kogenate FS, "product will be available for emergency use.
This includes results from a study comparing the pharmacokinetic profiles of Kovaltry, Bayers unmodified, full-length, recombinant human factor VIII (FVIII), versus Kogenate Bayer (sucrose-formulated recombinant factor VIII), as well as interim data on a study of children with severe hemophilia A in China.
Among the established products, the blood-clotting medicine Kogenate posted significant sales gains in comparison with a weak prior-year quarter.
Delivery device is key contributor to growth of Kogenate franchise 88
The approval of Kovaltry builds upon Bayers growing hematology portfolio which also includes Kogenate Bayer, a product currently on the market in more than 70 countries globally, as well as a long-acting recombinant factor VIII pipeline candidate.
The approvals of Kovaltry build upon Bayers growing hematology portfolio which also includes Kogenate Bayer, a product currently on the market in more than 70 countries, as well as a long-acting recombinant factor VIII pipeline candidate.
Subject to the level of Bayer's Kogenate sales for the remainder of the agreed royalty-paying period, Ipsen could receive from Bayer in 2009 approximately [euro]36 million.
EU has given nod to Bayer for Kovaltry, a haemophilia treatment that expands the company's big-selling Kogenate franchise.
The bright spots were Nexavar and Kogenate, which posted
The European approval of Kovaltry builds upon Bayers growing hematology portfolio which also includes Kogenate Bayer, a product currently on the market in more than 70 countries globally, as well as a long-acting recombinant factor VIII pipeline candidate.
demonstrate non-inferiority against Bayer's Kogenate.